Headache News and Research

Latest Headache News and Research

Study shows MIRAPEX(R) (pramipexole) relieves patients with restless legs syndrome

Results from a large-scale, randomized, double-blind study show MIRAPEX(R) (pramipexole) provides rapid relief in patients with restless legs syndrome (RLS).

28 Apr 2004

Study shows ZOMIG nasal spray to be an effective treatment for migraine headaches

Results of a new multicenter U.S. study of almost 1,900 patients experiencing more than 3,400 migraine attacks confirm that treatment with ZOMIG(R) (zolmitriptan) Nasal Spray provides a very fast onset of action and long-lasting relief from migraine headache and associated symptoms.

27 Apr 2004

Antiepileptic drug levetiracetam (Keppra) shown to help chronic daily headaches

The antiepileptic drug levetiracetam (Keppra(R)) significantly reduced the frequency and impact of headaches in patients diagnosed with transformed migraine, according to a new study presented today at the 56th annual meeting of the American Academy of Neurology (AAN).

27 Apr 2004

Canadian company requested to ship Dengue Fever test kits to Hong Kong immediately

Medical Services International Inc. has announced that it has been requested to ship VScan Dengue Fever test kits to Hong Kong immediately.

27 Apr 2004

Women who have migraines with aura have a more than 50 percent increased risk of total stroke and 70 percent increase of ischemic stroke

Women who have migraines with aura have a more than 50 percent increased risk of total stroke and 70 percent increase of ischemic stroke compared to those without migraines, according to research that will be presented at the American Academy of Neurology 56th Annual Meeting

27 Apr 2004

Parkinson’s disease drug Pergolide effective in treating restless legs syndrome

Pergolide, a drug commonly used to treat Parkinson’s disease symptoms, has recently been shown to be effective in treating restless legs syndrome. Researchers from seven countries collaborated on the study, published in the April 27 issue of Neurology, the scientific journal of the American Academy of Neurology.

26 Apr 2004

Third Annual Encephalitis Conference

International organizers are proud to announce the FACES to FACES Encephalitis Conference, to be held in Enfield Connecticut USA on August 6th to August 8th, 2004.

26 Apr 2004

Los Angeles health officials urge public to take preventative measures against West Nile virus

Los Angeles health officials have issued a statement urging the public to take precautions against mosquitoes after crows in the county tested positive for the West Nile virus. "These findings are a clear warning that the virus is continuing to circulate and amplify in the environment. Now is the time to take precautions," said Steve West of the San Gabriel Valley Mosquito and Vector Control District.

24 Apr 2004

The April 2004 issue of Otolaryngology focuses on head and neck surgery

The efficacy of a new cancer-fighting virus is tested in the study, “Treatment of Solid Sarcomas in Immunocompetent Mice with Novel Oncolytic Herpes Simplex Viruses.” A team of multi-disciplinary Japanese researchers found that a weakened version of herpes simplex virus (HSV) effectively eradicated neck and flank tumors in mice.

23 Apr 2004

FDA approval for drug to treat attention deficit hyperactivity disorder

McNeil Consumer & Specialty Pharmaceuticals has received an approvable letter from the U.S. Food and Drug Administration (FDA) for the use of CONCERTA® (methylphenidate HCl) CII Extended-release Tablets in adolescents with Attention Deficit/Hyperactivity Disorder (ADHD) and to expand labeling to include a 72 mg dosing regimen.

22 Apr 2004

FDA accepts REMICADE® (infliximab) for the treatment of early rheumatoid arthritis

Centocor, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted its filing of a supplemental Biologics License Application (sBLA) for REMICADE® (infliximab) as first-line therapy, in combination with methotrexate, for the treatment of early rheumatoid arthritis (RA) patients with moderately-to-severely active disease. REMICADE®, in combination with methotrexate, is currently indicated in the U.S. for reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately-to-severely active RA who have had an inadequate response to methotrexate alone.

6 Apr 2004

First Approval in Europe of Ezetimibe/Simvastatin for treatment of elevated cholesterol

Merck/Schering-Plough Pharmaceuticals today announced the regulatory approval of INEGYTM (ezetimibe/simvastatin) in Germany for the treatment of elevated cholesterol (hypercholesterolemia). INEGY is the first product to reduce low-density lipoprotein cholesterol (LDL-C or ‘bad’ cholesterol), along with diet and exercise, through dual inhibition by inhibiting cholesterol production in the liver and absorption in the intestine. The approval of INEGY in Germany represents the first approval in Europe for ezetimibe/simvastatin tablets and the first step in seeking marketing approval throughout the European Union (EU) under the EU’s mutual recognition procedure.

4 Apr 2004

GenVec malaria vaccine initiative and the U.S. Naval Medical Research Center has announced partnership for malaria vaccine

GenVec, Inc., PATH's Malaria Vaccine Initiative (MVI), and the U.S. Naval Medical Research Center (NMRC) today announced a dynamic partnership to assess whether five malaria antigens, or proteins, can generate strong immune responses alone or in combination. This partnership will advance and expand the ongoing malaria vaccine development program between GenVec and NMRC. Malaria is one of the world's three leading infectious disease killers.

31 Mar 2004

A simple dietary supplement may also help to prevent strokes

A simple dietary supplement may not only give relief to some of the more than 400,000 New Zealanders that suffer from the pain of migraine headaches, but may also help to prevent strokes.

28 Mar 2004

Study shows Levitra enhances patients' self-esteem by improving erections

The first clinical study to evaluate LEVITRA™ (vardenafil HCl) in men with mild Major Depressive Disorder (MDD) and erectile dysfunction (ED) showed LEVITRA produced statistically significant improvements over baseline in all measures of erectile function (EF) and depression/self-esteem. In the study, men taking Levitra were nearly three times more likely to report improved erections than men taking placebo.

24 Mar 2004

Raptiva, 20 percent improvement in an individual's signs and symptoms of arthritis.

Genentech, Inc. and XOMA Ltd. today announced preliminary results of a randomized, placebo-controlled Phase II study with RAPTIVA™ (efalizumab) in 107 patients with psoriatic arthritis. The study did not reach statistical significance at 12 weeks (84 days) for the primary endpoint, ACR 20 response. An ACR 20 response indicates at least a 20 percent improvement in an individual's signs and symptoms of arthritis.

22 Mar 2004

New Treatment for Chronic Head Pain

Dr. Levy pioneered a procedure known as supraorbital nerve stimulation or SOS, in which neurotransmitters are implanted into the forehead to block head pain. Tiny wires are burrowed under the skin until the precise location of pain is marked by a tingling response to electrical charge. The wires are kept in place for a week, and if pain is lessened and the patient is comfortable with the technology, neurotransmitters are surgically implanted under local anesthesia. The patient is able to control pain relief by manually adjusting the level of electrical stimulation through a hand held device.

22 Mar 2004

FDA approves new chewable formulation of Zyrtec® aimed at young allergy sufferers

Pfizer Inc and UCB Pharma today announced the approval of a new chewable formulation of Zyrtec® (cetirizine HCl) for the treatment of seasonal and perennial allergic rhinitis (inflammation of the nasal passages) and chronic idiopathic urticaria (itching and hives of unknown causes) in children aged two years and older. The approval by the US Food and Drug Administration makes Zyrtec the first and only prescription antihistamine available in both syrup and chewable form.

22 Mar 2004

Headache News and Research

Latest Headache News and Research

Study shows MIRAPEX(R) (pramipexole) relieves patients with restless legs syndrome

Study shows ZOMIG nasal spray to be an effective treatment for migraine headaches

Antiepileptic drug levetiracetam (Keppra) shown to help chronic daily headaches

Canadian company requested to ship Dengue Fever test kits to Hong Kong immediately

Women who have migraines with aura have a more than 50 percent increased risk of total stroke and 70 percent increase of ischemic stroke

Parkinson’s disease drug Pergolide effective in treating restless legs syndrome

Third Annual Encephalitis Conference

Los Angeles health officials urge public to take preventative measures against West Nile virus

The April 2004 issue of Otolaryngology focuses on head and neck surgery

FDA approval for drug to treat attention deficit hyperactivity disorder

FDA accepts REMICADE® (infliximab) for the treatment of early rheumatoid arthritis

First Approval in Europe of Ezetimibe/Simvastatin for treatment of elevated cholesterol

GenVec malaria vaccine initiative and the U.S. Naval Medical Research Center has announced partnership for malaria vaccine

A simple dietary supplement may also help to prevent strokes

Study shows Levitra enhances patients' self-esteem by improving erections

Raptiva, 20 percent improvement in an individual's signs and symptoms of arthritis.

New Treatment for Chronic Head Pain

FDA approves new chewable formulation of Zyrtec® aimed at young allergy sufferers

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Headache News and Research

Latest Headache News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in